Edwards Lifesciences EW Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $380.7M+317% | $91.2M-68.6% | $290.3M-12.4% | $331.5M-7.0% | $356.4M-7.3% | ||
| $40.9M-4.2% | $42.7M+8.9% | $39.2M+2.9% | $38.1M+4.1% | $36.6M-14.1% | ||
| $45.4M+15.8% | $39.2M-4.9% | $41.2M+9.9% | $37.5M-6.7% | $40.2M+26.8% | ||
| $1.6M+115% | -$11M— | $0+100% | -$41.6M-41,700% | $100K-99.8% | ||
| -$347.1M-306% | $168.7M-25.4% | $226.1M+118% | $103.7M+200% | -$103.4M— | ||
| $18.1M+570% | $2.7M-65.8% | $7.9M— | —— | $28.6M+65.3% | ||
| $41.9M— | —— | -$10.2M+95.8% | -$240.4M-570% | $51.2M+110% | ||
| $43.8M-90.3% | $450.9M-21.4% | $573.7M+97.7% | $290.2M+3.5% | $280.4M— | ||
| $64.9M-33.4% | $97.4M+69.4% | $57.5M+16.6% | $49.3M-12.0% | $56M+12.4% | ||
| $6.3M-58.0% | $15M+900% | $1.5M-96.9% | $48.3M— | $0-100% | ||
| $641.1M-22.4% | $826.6M-17.9% | $1.01B+61.2% | $624.3M-1.6% | $634.5M+66.5% | ||
| $12.5M+58.2% | $7.9M-64.4% | $22.2M+55.2% | $14.3M-19.2% | $17.7M+149% | ||
| -$92.8M+53.2% | -$198.3M+53.6% | -$427.8M-149% | -$172.1M-302% | $85.3M— | ||
| $421.8M+939% | $40.6M-93.1% | $588.7M+10,604% | $5.5M-97.9% | $258.6M+158% | ||
| -$451.2M-3,858% | -$11.4M+98.5% | -$740.1M— | $0+100% | -$258M— | ||
| $8.2M— | $0+100% | -$1M+96.6% | -$29.6M-67.2% | -$17.7M-135% | ||
| -$492M— | —— | -$595.2M-522% | $141.2M+56.9% | $90M— | ||
| $123.6M— | —— | —— | $47.1M— | $0— | ||
| $65.2M— | $0— | —— | —— | $0-100% | ||
| -$3.5M— | —— | —— | —— | -$12.5M— | ||
| $117.9M— | —— | —— | $24.9M-43.0% | $43.7M+141% | ||
| -$9.4M-117% | $54.4M+202% | $18M-13.9% | $20.9M-14.0% | $24.3M-75.3% | ||
| -$50M-238% | -$14.8M-18.4% | -$12.5M0.0% | -$12.5M+65.9% | -$36.7M-194% | ||
| $8.7M+40.3% | $6.2M-56.3% | $14.2M+2.2% | $13.9M+231% | -$10.6M— | ||
| $6.5M-1.5% | $6.6M-2.9% | $6.8M+6.3% | $6.4M+4.9% | $6.1M-1.6% | ||
| -$500K+90.7% | -$5.4M— | —— | -$4.7M-30.6% | -$3.6M+65.7% | ||
| $0-100% | $5.5M+112% | $2.6M-81.4% | $14M+367% | $3M-90.0% | ||
| $300K— | $0-100% | $4.5M+28.6% | $3.5M+3,600% | -$100K-101% | ||
| $12.5M+12,400% | $100K-99.6% | $24.4M+307% | $6M-53.1% | $12.8M+33.3% | ||
| $55.2M+16.2% | $47.5M+108% | $22.8M-56.8% | $52.8M+197% | $17.8M-49.1% | ||
| $710.1M+0.5% | $706.6M+5.5% | $669.7M+9.5% | $611.8M-26.1% | $827.9M+217% | ||
| $1.7M+155% | -$3.1M-29.2% | -$2.4M-340% | $1M+42.9% | $700K— | ||
| $68.9M+113% | $32.3M-6.9% | $34.7M-39.3% | $57.2M+14.6% | $49.9M+74.5% | ||
| $0— | —— | —— | —— | $36.3M— | ||
| $100M— | —— | -$50M— | —— | $50M— | ||
| $35.1M— | $0— | —— | —— | $0-100% | ||
| -$21.1M-106% | $353.5M-31.5% | $516.2M+114% | $240.9M+7.4% | $224.4M— | ||
| -$21.1M-106% | $353.5M-31.5% | $516.2M+114% | $240.9M+7.4% | $224.4M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Edwards Lifesciences generate?
- Edwards Lifesciences (EW) generated $1.4B in operating cash flow over the trailing twelve months.
- What is Edwards Lifesciences's free cash flow?
- After $269.1M of capital expenditures, Edwards Lifesciences's free cash flow was $1.1B over the trailing twelve months, up 57.5% year over year.
- Where does Edwards Lifesciences's cash flow data come from?
- Every line is extracted from Edwards Lifesciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
